Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
AbbVie Biotechnology Limited v. The Mathilda and Terence Kennedy Institute of Rheumatology Trust
Case Number:
1:11-cv-02541
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
June 26, 2013
AbbVie Gets Humira Patent Invalidated As Obvious
AbbVie Inc. has won a ruling in New York federal court declaring invalid a patent for the anti-inflammatory drug Humira held by the Mathilda and Terence Kennedy Institute of Rheumatology Trust, meaning the drugmaker no longer will have to pay the trust licensing fees.
-
October 14, 2011
Trust Can't Boot Abbott's Humira Patent Challenge
A New York federal judge on Friday shot down a move by the Mathilda and Terence Kennedy Institute of Rheumatology Trust to dismiss Abbott Biotechnology Ltd.'s suit over the institute's patent allegedly covering the anti-inflammatory drug Humira.